The evaluation of the CD4+CD25+Foxp3+ T cells determined that the administration of TEXomiR significantly (p < 0.05) decreased the tumor-infiltrated regulatory T cells compared with the PBS-treated group (Figure 8). Here, CD4 is linked to neoplasm.